16 completed, 5 terminated, 3 active not recruiting, 2 unknown. 11 Phase 3, 10 Phase 2, 7 Phase 4, 3 Phase 1.
Follow Prothya Biosolutions: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema Dupilumab - Atopic Dermatitis, Atopic Dermatitis Eczema | Phase 4 | Active not recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 216 | 2023-08-14 | 2026-10-29 |
| Dose-Response in PD and Safety of Cofact Under VKA Anticoagulation Cofact - Healthy Volunteers | Phase 1 / Phase 2 | Completed | Prothya Biosolutions | 69 | 2021-11-12 | 2024-04-08 |
| Add-on Intravenous Immunoglobulins in Early Myositis Immune Globulin Intravenous (Human), Placebo - Inflammatory Myopathy, Idiopathic, Dermatomyositis | Phase 2 / Phase 3 | Active not recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 44 | 2021-09-13 | 2026-02-27 |
| Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study) ConvP, FFP - Covid19 | Phase 3 | Terminated | Erasmus Medical Center | 420 | 2020-10-12 | 2022-04-01 |
| Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study) Convalescent plasma - COVID-19 | Phase 2 / Phase 3 | Terminated | Erasmus Medical Center | 86 | 2020-04-08 | 2022-04-01 |
| Data Registry of Auto Immune Hemolytic Anemia Autoimmune Hemolytic Anemia | Unknown | Sanquin Research & Blood Bank Divisions | 720 | 2019-07-12 | 2019-07-19 | |
| Apotransferrin in Patients With β-thalassemia human apotransferrin - β-thalassemia Intermedia | Phase 2 | Terminated | Prothya Biosolutions | 10 | 2019-03-21 | 2022-08-15 |
| Pharmacokinetics of New HepBQuin a human hepatitis B immunoglobulin solution for injection for intramuscular administration - Healthy | Phase 1 | Completed | Prothya Biosolutions | 24 | 2019-03-20 | 2019-09-19 |
| Cost-effectiveness of Adalimumab and Surgery vs Adalimumab in HS Wide Excision, Adalimumab Injection - Hidradenitis Suppurativa | Phase 4 | Unknown | Erasmus Medical Center | 128 | 2018-07-31 | 2019-02-08 |
| C1-inhibitor in Allergic ASThma Patients C1-inhibitor, Saline, Antibiotics - Asthma | Phase 4 | Terminated | T. van der Poll | 37 | 2016-11-16 | 2020-06-24 |
| Towards Personalized Dosing of Natalizumab in Multiple Sclerosis Natalizumab - Multiple Sclerosis | Phase 4 | Completed | Amsterdam UMC, location VUmc | 61 | 2016-11-03 | 2019-07-12 |
| Pharmacokinetics and Safety of IVIG Nanogam 100 mg/ml Intravenous immunoglobulin infusion - Primary Immunodeficiency | Phase 3 | Completed | Prothya Biosolutions | 23 | 2013-12-01 | 2015-04-06 |
| In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia - VECTOR II C1-esterase inhibitor, Endotoxin - Innate Immune Response, Endotoxemia | Phase 3 | Completed | Radboud University Medical Center | 20 | 2013-09-01 | 2014-12-02 |
| Effect of C1-esterase Inhibitor on Systemic Inflammation in Trauma Patients With a Femur or Pelvic Fracture C1-esterase inhibitor, Saline 0.9% - Trauma, Inflammation | Phase 3 | Terminated | UMC Utrecht | 11 | 2012-04-01 | 2015-02-04 |
| Apotransferrin in Atransferrinemia Human apotransferrin - Congenital Atransferrinemia | Phase 2 | Active not recruiting | Prothya Biosolutions | 5 | 2010-12-01 | 2026-09-16 |
| Intravenous Immunoglobulin (IVIg) for Parvovirus B19(PVB19) Mediated Cardiomyopathy Intravenous Immunoglobulins, plasma volume expander - Myocardial Diseases, Parvovirus B19, Human | Phase 3 | Completed | Prothya Biosolutions | 50 | 2009-11-01 | 2018-08-29 |
| Treatment of Deficient Subclass or Anti-polysaccharide Antibody Response intravenous immunoglobulins, antibiotics - IgG Deficiency, Infections | Phase 4 | Completed | Prothya Biosolutions | 55 | 2007-11-01 | 2015-04-06 |
| C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema C1 inhibitor concentrate (C1-esteraseremmer-N) - Angioedema | Phase 2 / Phase 3 | Completed | Prothya Biosolutions | 6 | 2006-11-01 | 2009-05-04 |
| C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema C1 inhibitor concentrate (C1-esteraseremmer-N) - Angioedema | Phase 3 | Completed | Prothya Biosolutions | 15 | 2006-02-01 | 2009-05-04 |
| Kinetics, Efficacy and Safety of C1-Esteraseremmer-N C1 inhibitor concentrate - Hereditary Angioedema Type I, Angioneurotic Edema | Phase 2 | Completed | Prothya Biosolutions | 12 | 2005-09-01 | 2009-05-04 |
Showing 20 of 26. Sign in to see all of them.
Angioedema (3) · Hereditary Angioedema Types I and II (3) · Acquired angioedema (2) · Angioedemas, Hereditary (2) · COVID-19 (2) · Inflammation (2) · Sepsis (2) · Agammaglobulinemia (1) · Anemia (1) · Anemia, Hemolytic, Autoimmune (1) · Antisynthetase syndrome (1) · Asthma (1) · Cardiomyopathies (1) · Congenital atransferrinemia (1) · Dermatitis, Atopic (1)
Complement C1 Inhibitor Protein (3) · Immunoglobulins, Intravenous (3) · Sodium Chloride (3) · Anti-Bacterial Agents (2) · Adalimumab (1) · Ciprofloxacin (1) · Endotoxins (1) · Factor IX (1) · Injections (1) · Mannose-Binding Lectin (1) · Metronidazole (1) · Natalizumab (1) · Plasma Substitutes (1) · SERPING1 protein, human (1) · Vancomycin (1)
Netherlands (22) · Germany (2) · Belgium (1) · Italy (1) · Poland (1) · Spain (1)
M. M. Levi, Prof. Dr. (3) · Bart Rijnders, MD, PhD (2) · P FW Strengers, MD (2) · Alberto Piperno, MD, PhD (1) · Bart Biemond, MD, PhD (1) · DirkJan Hijnen, MD PhD (1) · E AM Sanders, PhD, MD (1) · E P Mauser-Bunschoten, MD, PdD (1) · F P Kroon, PhD, MD (1) · H N Caron (1) · Hans Hoeven, Prof (1) · J T van Dissel, PhD, MD (1) · Jan Prins, MD PhD (1)
PMID 21988742, PMID 28515092, PMID 33044747, PMID 33347677, PMID 34013969, PMID 34303860, PMID 35546145, PMID 36734509, PMID 37162745
2023 (1)